These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33079379)

  • 1. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
    Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
    J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial.
    Knoll W; Mallick R; Wells PS; Carrier M
    Thromb Res; 2021 Jan; 197():13-15. PubMed ID: 33160115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
    McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
    J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.
    Cohen AT; Dhamane AD; Liu X; Singh R; Han S; Stellhorn R; Wang J; Luo X
    J Natl Compr Canc Netw; 2024 Aug; 22(6):397-403. PubMed ID: 39151451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
    Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
    Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
    Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
    N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
    Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial.
    Ladha D; Mallick R; Wang TF; Caiano L; Wells PS; Carrier M
    Thromb Res; 2021 Jun; 202():151-154. PubMed ID: 33857789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
    Levine MN; Gu C; Liebman HA; Escalante CP; Solymoss S; Deitchman D; Ramirez L; Julian J
    J Thromb Haemost; 2012 May; 10(5):807-14. PubMed ID: 22409262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
    Liu X; Thompson J; Phatak H; Mardekian J; Porcari A; Johnson M; Cohen AT
    Thromb Haemost; 2016 Jan; 115(1):161-8. PubMed ID: 26446706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
    Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
    CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
    Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
    Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial.
    Nayak AL; Zahrai A; Mallick R; Wang TF; Delluc A; Castellucci LA; Carrier M; Wells PS
    Thromb Res; 2021 Dec; 208():79-82. PubMed ID: 34742140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
    Potere N; Di Nisio M; Porreca E; Wang TF; Tagalakis V; Shivakumar S; Delluc A; Mallick R; Wells PS; Carrier M
    Thromb Res; 2023 Jun; 226():82-85. PubMed ID: 37121015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.